ACRV icon

Acrivon Therapeutics

18 hedge funds and large institutions have $170M invested in Acrivon Therapeutics in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

Holders
18
Holders Change
+18
Holders Change %
% of All Funds
0.29%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
%
% of All Funds
0.03%
New
18
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
RCM
1
RA Capital Management
Massachusetts
$55.4M 4,810,508 +4,810,508 New
PA
2
Perceptive Advisors
New York
$34.7M 3,007,858 +3,007,858 New
SCV
3
Sands Capital Ventures
Virginia
$19M 1,652,605 +1,652,605 New
Citadel Advisors
4
Citadel Advisors
Florida
$18.2M 1,634,104 +1,634,104 New
Marshall Wace
5
Marshall Wace
United Kingdom
$14.1M 1,223,252 +1,223,252 New
Wellington Management Group
6
Wellington Management Group
Massachusetts
$9.99M 900,149 +900,149 New
Federated Hermes
7
Federated Hermes
Pennsylvania
$9.48M 823,300 +823,300 New
NMC
8
NEA Management Company
Maryland
$4.44M 481,677 +481,677 New
HM
9
HealthCor Management
New York
$3.27M 284,201 +284,201 New
Bank of Montreal
10
Bank of Montreal
Ontario, Canada
$545K 42,444 +42,444 New
Goldman Sachs
11
Goldman Sachs
New York
$447K 38,800 +38,800 New
Two Sigma Investments
12
Two Sigma Investments
New York
$248K 21,534 +21,534 New
Millennium Management
13
Millennium Management
New York
$226K 19,639 +19,639 New
DCM
14
DAFNA Capital Management
California
$180K 15,648 +15,648 New
UBS Group
15
UBS Group
Switzerland
$54.7K 4,748 +4,748 New
Barclays
16
Barclays
United Kingdom
$47K 4,142 +4,142 New
Morgan Stanley
17
Morgan Stanley
New York
$10K 869 +869 New
TRCT
18
Tower Research Capital (TRC)
New York
$2K 159 +159 New
CFGS
19
Concourse Financial Group Securities
Alabama